Trial Profile

A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Pegenzileukin (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Squamous cell cancer
Focus Proof of concept; Therapeutic Use
Acronyms Master Protocol; Pegathor Gastrointestinal 203
Sponsors Sanofi

02 Oct 2024 Status changed from active, no longer recruiting to discontinued based on strategic sponsor decision not driven by any safety concerns.
08 Mar 2024 This trial has been Discontinued in Italy according to European Clinical Trials Database record.
20 Feb 2024 Planned End Date changed from 31 Mar 2024 to 10 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com